Synonyms: GS-5885 | GS5885 | Harvoni® (ledipasvir + sofosbuvir)
ledipasvir is an approved drug (EMA & FDA (2014))
Compound class:
Synthetic organic
Comment: Ledipasvir is an orally available, direct-acting inhibitor of the hepatitis C virus (HCV) non-structural protein 5A (NS5A) replication complex [1].
|
|
Classification ![]() |
|
Compound class | Synthetic organic |
Approved drug? | Yes. EMA (2014) | FDA (2014) |
WHO Essential Medicine | WHO Essential Medicines List (EML) (23rd List, 2023). Access PDF version. Click to view more information about the WHO Model Lists of Essential Medicines. |
International Nonproprietary Names ![]() |
|
INN number | INN |
9796 | ledipasvir |
Synonyms ![]() |
GS-5885 | GS5885 | Harvoni® (ledipasvir + sofosbuvir) |
Database Links ![]() |
|
CAS Registry No. | 1256388-51-8 (source: WHO INN record) |
ChEMBL Ligand | CHEMBL2374220 |
DrugBank Ligand | DB09027 |
DrugCentral Ligand | 4899 |
GtoPdb PubChem SID | 434321706 |
PubChem CID | 67505836 |
Search Google for chemical match using the InChIKey | VRTWBAAJJOHBQU-KMWAZVGDSA-N |
Search Google for chemicals with the same backbone | VRTWBAAJJOHBQU |
Search PubMed clinical trials | ledipasvir |
Search PubMed titles | ledipasvir |
Search PubMed titles/abstracts | ledipasvir |
UniChem Compound Search for chemical match using the InChIKey | VRTWBAAJJOHBQU-KMWAZVGDSA-N |
UniChem Connectivity Search for chemical match using the InChIKey | VRTWBAAJJOHBQU-KMWAZVGDSA-N |
Product supplier links are provided as a service to assist in identifying commercial suppliers of reagents that are mentioned on the IUPHAR/BPS Guide to PHARMACOLOGY database website, and do not imply their endorsement by NC-IUPHAR.
Links are provided in return for sponsorship, used to fund improvements to this database. The sponsorship account is managed and audited by the University of Edinburgh, a charitable body registered in Scotland, SC005336. If you are interested in sponsoring the database, please contact us.
✖
Ledipasvir (links to external site)
Cat. No. HY-15602 |